Clinical trials: Axillary Hyperhidrosis
Hyperhidrosis
A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
This study is being conducted to assess the safety and efficacy of 3 concentrations of BBI-4000 and vehicle (4 treatment arms), applied for the treatment of axillary hyperhidrosis.
- Trial name
- NCT03024255
- Testing
- BBI-4000 gel, 5%, BBI-4000 gel, 10%, BBI-4000 gel, 15%
- Volunteers
- 227 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis
The purpose of this study is to establish the therapeutic range of ANT-1207 in the treatment of primary axillary hyperhidrosis.
- Trial name
- NCT02479139
- Testing
- Vehicle, ANT-1207
- Where
- 19 sites in United States
- Volunteers
- 145 people
- Sponsor
- Allergan
Hyperhidrosis
Feasibility Study: Safety and Efficacy of the Ulthera® System for Treatment of Axillary Hyperhidrosis
Up to 20 subjects will be treated. Subjects will receive two (2) bilateral Ultherapy™ or Sham treatments of the axilla. The study hypothesis is that subjects who receive Ultherapy™ treatment will have a greater reduction in…
- Trial name
- NCT01713673
- Testing
- Ulthera System Treatment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ulthera, Inc
Primary Axillary Hyperhidrosis
Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
The Sahara Study is a study to evaluate the safety and effectiveness of the N-SWEAT Patch for use in subjects with excessive axillary sweating, or primary focal axillary hyperhidrosis.
- Trial name
- NCT04599907
- Testing
- Roll-In Cohort: Single Application of N-SWEAT Patch, Randomized Cohort: Single Application of N-SWEAT Patch
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Candesant Biomedical, Inc.
Hyperhidrosis
Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis
The study is a randomized, double-blind, vehicle controlled, parallel group study, designed to assess the efficacy and safety of glycopyrronium topical wipes, once daily, compared to vehicle in subjects with axillary…
- Trial name
- NCT02530294
- Testing
- glycopyrronium Topical Wipes, Vehicle
- Where
- 20 sites in United States
- Volunteers
- 353 people
- Sponsor
- Journey Medical Corporation
Hyperhidrosis
A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis
This is a three year open-label study in subjects with axillary hyperhidrosis.
- Trial name
- NCT00168480
- Testing
- Botulinum Toxin Type A
- Where
- 4 sites in United States, Germany and 2 more
- Volunteers
- 424 people
- Sponsor
- Allergan
Hyperhidrosis
A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and treatment effect of BBI-4000 when topically applied to subjects with axillary hyperhidrosis.
- Trial name
- NCT02058264
- Testing
- BBI-4000
- Volunteers
- 18 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
Feasibility Study: Ulthera® System for the Treatment of Axillary Hyperhidrosis
Single-center, randomized, split-body, pilot study, treatment of up to 23 subjects in two treatment groups. Subjects will receive two Ultherapy treatments at Day 0 with follow-ups at 7 and 14 days post-treatment #1, and Day 28…
- Trial name
- NCT01713959
- Testing
- Ulthera System treatment
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Ulthera, Inc
Hyperhidrosis
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
This is a safety and efficacy study of botulinum toxin type A in subjects with primary axillary hyperhidrosis.
- Trial name
- NCT02565732
- Testing
- Botulinum toxin type A
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Revance Therapeutics, Inc.
Primary Axillary Hyperhidrosis
Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis
The aim of the study is to assess the safety, tolerability, pharmacokinetics (PK) and efficacy of escalating concentrations of GPB in subjects with axillary hyperhidrosis.
- Trial name
- NCT03037788
- Testing
- WO3979, WO3970, WO3992
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Hyperhidrosis
A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis
The purpose of this study is to evaluate the safety and efficacy of glycopyrrolate compared to vehicle for the treatment of axillary hyperhidrosis.
- Trial name
- NCT02016885
- Testing
- glycopyrrolate, 1.0%, glycopyrrolate, 2.0%, glycopyrrolate, 3.0%
- Where
- 21 sites in United States
- Volunteers
- 198 people
- Sponsor
- Journey Medical Corporation
Primary Axillary Hyperhidrosis
Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis.
The aim of this study is to investigate the efficacy and safety of 1% GPB cream after 4 weeks of treatment compared with placebo with a sufficient number of patients to obtain statistically significant results, and to assess the…
- Trial name
- NCT03658616
- Testing
- WO3970
- Where
- Germany
- Volunteers
- 518 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Hyperhidrosis Primary Focal Axilla
Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis
This study is intented to evaluate the efficacy and safety of MEDITOXIN compared to placebo in treatment of primary axillary hyperhidrosis.
- Trial name
- NCT03760198
- Testing
- Meditoxin
- Where
- South Korea
- Volunteers
- 220 people
- Sponsor
- Medy-Tox
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- CARDIGANII (NCT03948646)
- Testing
- Sofpironium Bromide, 15%, Vehicle
- Where
- 42 sites in United States
- Volunteers
- 351 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
The purpose of this study is to characterize the pharmacokinetics (PK), safety and tolerability of topically applied umeclidinium following single dose topical administration.
- Trial name
- NCT01934153
- Testing
- [14C]Umeclidinium 18.5 mg
- Where
- Netherlands
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Primary Axillary Hyperhidrosis
Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary Hyperhidrosis
The aim of this study is to investigate the safety, tolerability and efficacy of 1% GPB Cream compared to Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use under maximum use conditions.
- Trial name
- NCT04159610
- Testing
- WO3970, Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Primary Axillary Hyperhidrosis
Ulthera® System for Treating Axillary Hyperhidrosis
Up to 20 enrolled subjects will be treated. Subjects will receive two Ulthera® treatments on the axillas provided 30 days apart. Follow-up visits will occur at 7, 30, 90 and 180 days following the last treatment.
- Trial name
- NCT02286765
- Testing
- Ulthera System treatment
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ulthera, Inc
Hyperhidrosis
Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis
This is a double blind (sponsor unblind), repeat dose, randomized, parallel group, placebo controlled study to assess the pharmacokinetic parameters, safety, tolerability, and clinical effect of topically applied umeclidinium…
- Trial name
- NCT02563899
- Testing
- Umeclidinium, Vehicle
- Where
- 3 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Primary Axillary Hyperhidrosis
Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis
The purpose of this study is to confirm the effect of ANT-1403 in the treatment of primary axillary hyperhidrosis.
- Trial name
- NCT01799824
- Testing
- ANT-1403
- Where
- 9 sites in United States
- Volunteers
- 52 people
- Sponsor
- Anterios Inc.
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03627468
- Testing
- Sofpironium Bromide Gel, 5%, Sofpironium Bromide Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Botanix Pharmaceuticals